SCHEMBL7225632

SCHEMBL7225632

COc1ccc(NC(=O)CCn2c3c(c4ccccc42)CCN(C(=O)O)CC3)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
MAPT P10636 3/20 0.51
ALDH1A1 P00352 3/20 0.51
ALOX15 P16050 1/20 0.51
RXFP1 Q9HBX9 1/20 0.48
TP53 P04637 1/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
PTGDR2 Q9Y5Y4 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
HDAC6 Q9UBN7 1/20 0.45
MCL1 Q07820 1/20 0.45
NPC1 O15118 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7219447 0.90 SMN1; SMN2 (0.56) KMT2AMEN1MAPTALDH1A1RXFP1
SCHEMBL6475604 0.88 HDAC1 (0.49) KMT2AMEN1MAPTALDH1A1ALOX15
Hydrochloric Acid SCHEMBL6480850 0.84 MEN1 (0.53) KMT2AMEN1MAPTALDH1A1ALOX15
SCHEMBL6474125 0.80 PTGDR2 (0.64) KMT2AMEN1ALDH1A1KDM4EPTGDR2
SCHEMBL6531341 0.79 SMN1; SMN2 (0.52) KMT2AMEN1MAPTALDH1A1RXFP1
SCHEMBL7227263 0.77 PKM (0.49) KMT2AALDH1A1TP53KDM4EPTGDR2
SCHEMBL6481086 0.77 KDM4E (0.47) KMT2AMEN1MAPTALDH1A1RXFP1
SCHEMBL6474612 0.76 PTGDR2 (0.54) KMT2AMEN1ALDH1A1KDM4EPTGDR2
SCHEMBL6480591 0.76 KDM4E (0.55) KMT2AMEN1ALDH1A1KDM4EPTGDR2
SCHEMBL6474609 0.75 KDM4E (0.54) KMT2AMEN1ALDH1A1KDM4EPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583135-B2 Treating central nervous system disorders wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). PHARMACIA & UPJOHN COMPANY 2003-06-24 US disclosed